Nov 7, 2024 · Luspatercept (brand name Reblozyl) is used to treat anemia (low red blood cells) in certain patients with beta-thalassemia or myelodysplastic syndromes (MDS). Luspatercept …

Luspatercept ... Luspatercept, sold under the brand name Reblozyl, is a medication used for the treatment of anemia in beta thalassemia and myelodysplastic syndromes.

REBLOZYL® (luspatercept-aamt) is a prescription medicine used to treat anemia (low red blood cells) in adults with beta thalassemia who need regular red blood cell (RBC) transfusions.

Feb 1, 2025 · Luspatercept-aamt injection is used to treat anemia in patients with beta thalassemia who need regular red blood cell (RBC) transfusions.

Luspatercept-aamt is a recombinant fusion protein that binds several endogenous TGF-β superfamily ligands, thereby diminishing Smad2/3 signaling. Luspatercept-aamt promoted …

Luspatercept is a recombinant fusion protein consisting of a modified extracellular domain of the activin receptor type IIB (ActRIIB) fused with the Fc domain of immunoglobulin G1 (IgG1).

LUSPATERCEPT (lus PAT er sept) treats low levels of red blood cells (anemia) in the body in people with beta thalassemia or myelodysplastic syndromes. It works by helping the body …

This page contains brief information about luspatercept-aamt and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

Aug 2, 2024 · Find patient medical information for Reblozyl (luspatercept) on WebMD including its uses, side effects and safety, interactions, pictures, warnings, and user ratings

LUSPATERCEPT (lus PAT er sept) treats low levels of red blood cells (anemia) in the body in people with beta thalassemia or myelodysplastic syndromes. It works by helping the body …